About: Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center
Creator	Lee, Jun Lee, John Aull, Meredith Dadhania, Darshana Gingras, Laura Hartono, Choli Kapur, Sandip Kodiyanplakkal, Rosy Lubetzky, Michelle Marku-Podvorica, Jehona Muthukumar, Thangamani Saal, Stuart Sultan, Samuel Suthanthiran, Manikkam Craig-Schapiro, Rebecca Salinas, Thalia
Source	Medline; PMC
abstract	BACKGROUND: Kidney graft recipients receiving immunosuppressive therapy may be at heightened risk for coronavirus disease 2019 (Covid-19) and adverse outcomes. It is therefore important to characterize the clinical course and outcome of Covid-19 in this population and identify safe therapeutic strategies. METHODS: We performed a retrospective chart review of 73 adult kidney graft recipients evaluated for Covid-19 from 13 March to 20 April 2020. Primary outcomes included recovery from symptoms, acute kidney injury, graft failure and case fatality rate. RESULTS: Of the 73 patients screened, 54 tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—39 with moderate to severe symptoms requiring hospital admission and 15 with mild symptoms managed in the ambulatory setting. Hospitalized patients were more likely to be male, of Hispanic ethnicity and to have cardiovascular disease. In the hospitalized group, tacrolimus dosage was reduced in 46% of patients and mycophenolate mofetil (MMF) therapy was stopped in 61% of patients. None of the ambulatory patients had tacrolimus reduction or discontinuation of MMF. Azithromycin or doxycycline was prescribed at a similar rate among hospitalized and ambulatory patients (38% versus 40%). Hydroxychloroquine was prescribed in 79% of hospitalized patients. Graft failure requiring hemodialysis occurred in 3 of 39 hospitalized patients (8%) and 7 patients died, resulting in a case fatality rate of 13% among Covid-19-positive patients and 18% among hospitalized Covid-19-positive patients. CONCLUSIONS: Data from our study suggest that a strategy of systematic triage to outpatient or inpatient care, early management of concurrent bacterial infections and judicious adjustment of immunosuppressive drugs rather than cessation is feasible in kidney transplant recipients with Covid-19.
has issue date	2020-07-17(xsd:dateTime)
bibo:doi	10.1093/ndt/gfaa154
bibo:pmid	32678882
has license	no-cc
schema:url	https://doi.org/10.1093/ndt/gfaa154
resource representing a document's title	Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center
has PubMed Central identifier	PMC7454827
has PubMed identifier	32678882
schema:publication	Nephrol Dial Transplant
resource representing a document's body	covid:PMC7454827#body_text
is schema:about of	named entity 'cases' named entity 'immunosuppression' named entity 'CENTER' named entity 'ALLOGRAFT' named entity 'allograft' named entity 'Tacrolimus' named entity 'Covid' named entity 'kidney transplant' named entity 'Fever' named entity 'nausea' named entity 'follow-up' named entity 'antibody response' named entity 'kidney transplant' named entity 'comorbidities' named entity 'blood group' named entity 'immunosuppression' named entity 'Covid-19' named entity 'Covid' named entity 'general population' named entity 'Calcineurin inhibitors' named entity 'Covid' named entity 'ICU' named entity '4.7' named entity 'immunosuppressive therapy' named entity 'AKI' named entity 'observational study' named entity 'standard deviation' named entity 'symptomology' named entity 'immunosuppressive agents' named entity 'oxygen' named entity 'tacrolimus' named entity 'secondary bacterial infections' named entity 'Early diagnosis' named entity 'empiric treatment' named entity 'azithromycin' named entity 'Fever' named entity 'ventilator support' named entity 'Induction therapy' named entity 'd-dimer' named entity 'polymerase chain reaction' named entity 'kidney transplant' named entity 'Covid' named entity 'MERS-CoV' named entity 'polymerase chain reaction' named entity 'infection' named entity 'kidney transplant' named entity 'Institutional Review Board' named entity 'kidney' named entity 'dialysis' named entity 'SARS-CoV-2' named entity 'symptom' named entity 'SARS-CoV-2' named entity 'case reports' named entity 'transplant recipients' named entity 'immunosuppressive medications' named entity 'hypotensive' named entity 'coronavirus disease 2019' named entity 'receptor' named entity 'laboratory test' named entity 'Covid' named entity 'Prednisone' named entity 'airway' named entity 'nasal cannula' named entity 'chest pain' named entity 'belatacept' named entity 'Covid' named entity 'WCM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software